can not be faulted for the small sample size, which Dr. Stricker and Ms. Johnson blame for the poor statistical significance. The authors screened 3,368 patients to identify 37 subjects. Dr. Stricker criticized earlier studies⁸ that showed no benefit of prolonged treatment on the grounds that patients in those studies were ill an average of 3 years which is about a third of that in this study.

Dr. Stricker and Ms. Johnson's comparison of *Burgdorferi* to *Mycobacteria tuberculosis* repeats a common canard: comparing this extracellular, highly antibiotic-sensitive spirochete to an intracellular, often drug resistant, mycobacterium. Even in TB, patients are not subjected to the risk of 10+ weeks of intravenous access. Their assertions aside, it is acknowledged that standard treatment regimens are not 100% effective. Rather, it is clear from this and previous studies^{8,9} that prolonged courses of antibiotics are without significant merit and carry substantial risk.

John J. Halperin, Summit, NJ

Disclosure: Dr. Halperin has served as a defense expert in cases alleging failure to diagnose or treat nervous system Lyme disease. Dr. Halperin holds equity in Abbott, Bristol Myers Squibb, Johnson & Johnson, Schering Plough, and Vasogen.

Copyright © 2008 by AAN Enterprises, Inc.

1. Halperin JJ. Prolonged Lyme disease treatment. *Neurology* 2008;70:986–987.
2. Fallon BA, Keilp JG, Corbera KM, et al. A randomized, placebo-controlled trial of repeated intravenous antibiotic therapy for Lyme encephalopathy. *Neurology* 2008;70:992–1003.
3. Johnson L, Stricker RB. Treatment of Lyme disease: a medicolegal assessment. *Exp Rev Anti-Infect Ther* 2004;2:533–557.
4. Phillips SE, Harris NS, Horowitz R, Johnson L, Stricker RB. Lyme disease: scratching the surface. *Lancet* 2005;366:1771.
5. Stricker RB. Counterpoint: Long-term antibiotic therapy improves persistent symptoms associated with Lyme disease. *Clin Infect Dis* 2007;45:149–157.
6. Stricker RB, Johnson L. Lyme disease: a turning point. *Exp Rev Anti-Infect Ther* 2007;5:759–762.
7. Centers for Disease Control and Prevention 2007 Lyme Disease—United States, 2003–2005. *Morb Mortal Wkly Rep* 2007;56:573–576.
8. Klempner M, Hu L, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. *N Engl J Med* 2001;345:85–92.
9. Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. *Neurology* 2003;60:1923–1930.

CORRECTION

Surgical treatment of delayed epilepsy in hemiconvulsion-hemiplegia-epilepsy syndrome

In the article “Surgical treatment of delayed epilepsy in hemiconvulsion-hemiplegia-epilepsy syndrome” by D.W. Kim et al. (*Neurology*[®] 2008;70:2116–2122), there is an error in reference 27. The first author should be Auvin S instead of Aubin S. The reference should appear as follows:

27. Auvin S, Devisme L, Maurage CA, et al. Neuropathological and MRI findings in an acute presentation of hemiconvulsion-hemiplegia: a report with pathophysiologic implications. *Seizure* 2007;16:371–376.

Neurology®

CORRECTION

Neurology 2008;71;1381
DOI 10.1212/01.wnl.0000338443.54357.15

This information is current as of October 20, 2008

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/71/17/1381.full>

References

This article cites 1 articles, 0 of which you can access for free at:
<http://n.neurology.org/content/71/17/1381.full#ref-list-1>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.